Neurocrine announces positive data from Phase II schizophrenia treatment trial

Neurocrine Biosciences has reported positive results from its Phase II study of NBI-1117568, an oral schizophrenia treatment. The trial, NBI-‘568-SCZ2028, achieved its primary endpoint with a significant reduction in symptoms at a 20mg daily dose. The Positive and Negative Syndrome Scale (PANSS) score showed a notable decline from baseline to week six, with a placebo-adjusted mean reduction of 7.5 points and an 18.2-point drop overall.

Improvements were also observed in the Clinical Global Impression of Severity (CGI-S) and Marder Factor Scores. NBI-1117568 was well tolerated, with adverse event-related discontinuation rates similar to placebo. Common side effects included somnolence, dizziness, and headache, while gastrointestinal and cardiovascular issues were rare. Importantly, the treatment did not lead to significant weight gain or increased extrapyramidal symptoms.

Neurocrine’s portfolio includes other muscarinic receptor drugs, such as NBI-1117567, NBI-1117569, and NBI-1117570, and the in-house developed NBI-1076986.